RxDoctor Payments Data

Chelsea McGee, DO

Cardiovascular Disease · Wagoner, OKNPI 1093925810

Payments from drug & device makers

$1,126in general payments, 2019–2025

Across 53 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$185
  • Boston Scientific$175
  • Baxter Healthcare$154
  • Merck$94
  • Boehringer Ingelheim$92
  • Amarin Pharma, Inc.$90
  • plus $337 from 10 others

What the payments were for

  • Food & beverage$1,11299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,126 in reported general payments places this provider in the 30th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$194,013
Medicare patients
167
Services billed
3,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan156$164,578
OzempicSemaglutide134$163,557
EliquisApixaban146$154,529
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$104,484
TrulicityDulaglutide68$75,932
JardianceEmpagliflozin56$66,836
JanuviaSitagliptin Phosphate46$56,869
FarxigaDapagliflozin Propanediol27$34,856
XareltoRivaroxaban30$18,797
VascepaIcosapent Ethyl19$12,014
BrilintaTicagrelor11$8,672
Rosuvastatin Calcium307$6,888
Metoprolol Succinate451$5,660
Dexlansoprazole DrDexlansoprazole11$3,567
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$55$164,578156 claims
Novo NordiskOzempic$30$163,557134 claims
PfizerEliquis$55$154,529146 claims
Lilly USA, LLCTrulicity$13$75,93268 claims
Boehringer IngelheimJardiance$92$66,83656 claims
MerckJanuvia$94$56,86946 claims
AstraZenecaFarxiga, Brilinta$29$43,52838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Wagoner

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →